Longeveron Inc. announced additional new clinical and biomarker results from its Phase 2a CLEAR MIND trial of its investigational product Lomecel-B? for the treatment of mild Alzheimer?s disease. The expanded data set reinforced the earlier top-line findings showing that the primary safety endpoint was met and provided further support for Lomecel-B?s positive benefit/risk profile. Additional analysis of cognitive function and daily living data consistently showed favorable results with Lomecel-B? over placebo in a dose-response fashion, with administration of Lomecel-B? associated with slowing and in some cases improving certain measurements of cognitive function (MoCA, MMSE).

New analyses of imaging data measured using MRI showed that administration of Lomecel-B? was associated with reduced neuroinflammation assessed by Diffusion Tensor Imaging (DTI), and also appeared to counter loss in brain volume in areas associated with Alzheimer?s disease (TBV, hippocampus, ventricles, thalamus).